

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987)

[ID6619]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder highlighted that ethnic minorities and deprived groups are often underrepresented in trials. The TRANSFORM study for liso-cel may reflect this. Real-world data is needed to understand outcomes in these patients.

A stakeholder noted that access to treatment with lisocabtagene may be difficult because:

- Treatment will predominantly be in the inpatient setting in tertiary care centres meaning that patients living further away from the tertiary centres will have an associated greater travel burden.
 - But reduced toxicity with liso-cel, compared to stem cell transplant and axicel, enables more ambulatory post-infusion care, with potential for follow-up to shift to referring centres, easing financial and travel burdens for patients and carers.

A stakeholder noted that CAR T therapy is complex, and many patients may struggle to understand written information due to language barriers or illiteracy therefore patient education should include translated materials and diverse media formats

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee can only appraise the technology within its marketing authorisation and based on the evidence available. The committee will consider whether its recommendation has any impact on potential equality issues or health inequalities, The committee should be mindful of the extent to which their recommendations could disadvantage a particular group.

Issues related to access to services, such as geographical location and accessibility cannot be addressed in a health technology evaluation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

N/a

Approved by Associate Director (name): ...Lorna Dunning
Date: 24/11/2025